USE OF C-MET PROTEIN FOR PREDICTING THE EFFICACY OF ANTI-HEPATOCYTE GROWTH FACTOR ('HGF') ANTIBODIES IN ESOPHAGEAL AND GASTRIC CANCER PATIENTS.

摘要

The present invention relates to use of the human Met receptor (also known as "c-Met") for predicting the efficacy of inhibitors of the HGF-Met pathway, and in particular, anti-HGF antibodies, in the treatment of esophageal and gastric cancer patients. The present invention also relates to methods and kits for predicting the usefulness of anti-HGF antibodies in the treatment of esophageal and gastric cancer.